Authors: Hazan S, Dave S, Gunaratne AW, Dolai S, Clancy RL, McCullough PA et al. PMID: 35135310 PMCID: PMC8826831 DOI: 10.2217/fmb-2022-0014 Abstract Aims: Ivermectin is a safe, inexpensive and effective early COVID-19 treatment validated in 20+ random, controlled trials. Having developed combination therapies for Helicobacter pylori, the authors present a highly effective COVID-19 therapeutic [...]

Authors: Cereda G, Ciappolino V, Boscutti A, Cantu F, Enrico P, Oldani L PMID: 34634109 PMCID: PMC8524565 DOI: 10.1093/advances/nmab110 Abstract The outbreak of the pandemic associated with Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) led researchers to find new potential treatments, including nonpharmacological molecules such as zinc (Zn2+). Specifically, the use of Zn2+ as a [...]

Authors: Gutierrez-Castrellon P, Gandara-Marti T, Abreu AT, Nieto-Rufino CD, Lopez-Orduna E PMID: 35014600 PMCID: PMC8757475 DOI: 10.1080/19490976.2021.2018899 Abstract Intestinal bacteria may influence lung homeostasis via the gut-lung axis. We conducted a single-center, quadruple-blinded, randomized trial in adult symptomatic Coronavirus Disease 2019 (Covid19) outpatients. Subjects were allocated 1:1 to probiotic formula (strains Lactiplantibacillus plantarum KABP022, KABP023, [...]

Authors: Izquierdo JL, Soriano JB, Gonzalez Y, Lumbreras S PMID: 35084258 PMCID: PMC8795755 DOI: 10.1177/00368504221074574 Abstract Infection by SARS-CoV-2 causing coronavirus disease 2019 (COVID-19) can be associated with serious and life-threatening conditions, including acute respiratory distress syndrome (ARDS). Severity and mortality have been related to a cytokine storm, an imbalance of oxidative stress, and a [...]

Authors: Patterson BK, Francisco EB, Yogendra R, Long E, Pise A, Hall E et al. PMID: 35082777 PMCID: PMC8784688 DOI: 10.3389/fimmu.2021.746021 AbstractThe recent COVID-19 pandemic is a treatment challenge in the acute infection stage but the recognition of chronic COVID-19 symptoms termed post-acute sequelae SARS-CoV-2 infection (PASC) may affect up to 30% of all infected [...]

Authors: Santamarina MG, Beddings I, Martinez Lomakin F, Boisier Riscal D PMID: 34980198 PMCID: PMC8721481 DOI: 10.1186/s13054-021-03885-y Abstract Background: SARS-CoV-2 seems to affect the regulation of pulmonary perfusion. Hypoperfusion in areas of well-aerated lung parenchyma results in a ventilation-perfusion mismatch that can be characterized using subtraction computed tomography angiography (sCTA). This study aims to evaluate [...]

Authors: Clemency BM, Varughese R, Morse CG, Koster DJ, Blaiss MS PMID: 34807241 PMCID: PMC8609464 DOI: 10.1001/jamainternmed.2021.6759 Abstract Importance: Systemic corticosteroids are commonly used in treating severe COVID-19. However, the role of inhaled corticosteroids in the treatment of patients with mild to moderate disease is less clear. Objective: To determine the efficacy of the inhaled [...]

Authors: Kumar P, Osahon O, Vides DB, Hanania N, Minard CG PMID: 35052554 PMCID: PMC8773164 DOI: 10.3390/antiox11010050 Abstract Humanity is battling a respiratory pandemic pneumonia named COVID-19 which has resulted in millions of hospitalizations and deaths. COVID-19 exacerbations occur in waves that continually challenge healthcare systems globally. Therefore, there is an urgent need to understand [...]

In this brief communication we are showing original research results with early estimates from Danish nationwide databases of vaccine effectiveness (VE) against the novel SARS-CoV-2 Omicron variant (B.1.1.529) up to five months after a primary vaccination series with the BNT162b2 or mRNA-1273 vaccines. Our study provides evidence of protection against infection with the Omicron variant after completion of a primary vaccination series with the BNT162b2 or mRNA-1273 vaccines; in particular, we found a VE against the Omicron variant of 55.2% (95% confidence interval (CI): 23.5 to 73.7%) and 36.7% (95% CI: 69.9 to 76.4%) for the BNT162b2 and mRNA-1273 vaccines, respectively, in the first month after primary vaccination. However, the VE is significantly lower than that against Delta infection and declines rapidly over just a few months. The VE is re-established upon revaccination with the BNT162b2 vaccine (54.6%, 95% CI: 30.4 to 70.4%).

Authors: Jayk Bernal A, da silva G, Musungaie DB, Kovalchuk A, Brown ML, Assaid C PMID: 34914868 PMCID: PMC8693688 DOI: 10.1056/NEJMoa2116044 Abstract Background: New treatments are needed to reduce the risk of progression of coronavirus disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is active against severe acute respiratory syndrome coronavirus 2 [...]